Skip to main content

Table 3 Association of circulating PCSK9 with incident type 2 diabetes in females

From: Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study

 

PCSK9

p for trend

Q1

n = 704

Q2

n = 705

Q3

n = 704

Q4

n = 704

Incidence of type 2 diabetes %

45 (6.4)

96 (13.6)

105 (14.9)

115 (16.4)

< 0.001

Model 1 HR (95% CI)

1.00

2.20 (1.17–4.14)

2.28 (1.21–4.26)

2.57 (1.39–4.77)

< 0.001

Model 2 HR (95% CI)

1.00

2.01 (1.06–3.79)

2.19 (1.17–4.10)

2.31 (1.24–4.31)

< 0.001

Model 3 HR (95% CI)

1.00

1.96 (1.04–3.71)

2.17 (1.16–4.07)

2.23 (1.20–4.16)

< 0.001

Model 4 HR (95% CI)

1.00

1.96 (1.04–3.70)

2.14 (1.14–4.01)

2.22 (1.19–4.13)

0.002

Model 5 HR (95% CI)

1.00

1.87 (0.99–3.53)

2.13 (1.14–4.00)

2.16 (1.16–4.04)

0.006

  1. Model 1 was adjusted for age. Model 2 was adjusted for the variable in model 1 plus smoking, drinking, physical activity, and educational attainment. Model 3 was adjusted for the variables in model 2 plus BMI. Model 4 was adjusted for the variables in model 3 plus waist circumference. Model 5 was adjusted for the variables in model 4 plus TG, LDL-C, SBP, ALT, AST, GGT, CRP, and HOMA-IR. Subjects with a baseline circulating PCSK9 level in the lowest quartile group served as the reference group. Cutoff values in the four groups were Q1 < 220.20 ng/mL, Q2 220.21–272.36 ng/mL, Q3 272.37–342.61 ng/mL, and Q4 > 342.62 ng/mL for females